J Clin Oncol 2020 Jul 30
Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.
Abstract
Purpose
To independently evaluate the impact of axillary surgery type and regional lymph node radiation (RLNR) on breast cancer-related lymphedema (BCRL) rates in patients with breast cancer.
Patients and methods
From 2005 to 2018, 1,815 patients with invasive breast cancer were enrolled in a lymphedema screening trial. Patients were divided into the following 4 groups according to axillary surgery approach: sentinel lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection (ALND) alone, and ALND+RLNR. A perometer was used to objectively assess limb volume. All patients received baseline preoperative and follow-up measurements after treatment. Lymphedema was defined as a ≥ 10% relative increase in arm volume arising > 3 months postoperatively. The primary end point was the BCRL rate across the groups. Secondary end points were 5-year locoregional control and disease-free-survival.
Results
The cohort included 1,340 patients with SLNB alone, 121 with SLNB+RLNR, 91 with ALND alone, and 263 with ALND+RLNR. The overall median follow-up time after diagnosis was 52.7 months for the entire cohort. The 5-year cumulative incidence rates of BCRL were 30.1%, 24.9%, 10.7%, and 8.0% for ALND+RLNR, ALND alone, SLNB+RLNR, and SLNB alone, respectively. Multivariable Cox models adjusted for age, body mass index, surgery, and reconstruction type showed that the ALND-alone group had a significantly higher BCRL risk (hazard ratio [HR], 2.66; P = .02) compared with the SLNB+RLNR group. There was no significant difference in BCRL risk between the ALND+RLNR and ALND-alone groups (HR, 1.20; P = .49) and between the SLNB-alone and SLNB+RLNR groups (HR, 1.33; P = .44). The 5-year locoregional control rates were similar for the ALND+RLNR, ALND-alone, SLNB+RLNR, and SLNB-alone groups (2.8%, 3.8%, 0%, and 2.3%, respectively).
Conclusion
Although RLNR adds to the risk of lymphedema, the main risk factor is the type of axillary surgery used.
Related Questions
What are your top takeaways in Breast Cancer from ASTRO 2024?
There were a number of important presentations on breast cancer at the ASTRO 2024 meeting. The three randomized trial discussed below stood out.1. Abstract 1: Poppe MM, et al.: A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHA...
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
Based on FABREC, we do offer hypofractionation after reconstruction and focus on plan quality with dose homogeneity and very selective use of bolus. RT CHARM will further clarify. LV bypass helps to reduce lymphedema risk and we don’t change fractionation based on that. Conroy, Cancer Network 2023
In light of the AMAROS trial, how do you decide between ALND vs. axillary RT?
These clinical scenarios will be faced more often by radiation oncologists.In the old French and NSABP B4 data, the regional control rates between surgery and radiation were very similar for clinically node negative patients, but these studies did not gain much traction because chemotherapy decision...